|

Afimkibart Clinical Trials

2 actively recruiting trials across 2 locations

No change since July 2026

Also known as: PF 06480605, PF-06480605, RO7790121, RVT-3101

Pipeline

Phase 2: 2

Top Sponsors

  • Hoffmann-La Roche2

Indications

Peoria, Arizona1 trial

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

SunValley Arthritis Center Ltd.

Phase 2

Tamarac, Florida1 trial

An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

West Broward Rheumatology Associates, Inc.

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.